Dealstreet

SAM, Vertices Partners, CAM lead on ChrysCapital 700 crore investment in Corona Remedies

ChrysCapital is acquiring 27 percent stake in Corona Remedies

Bar & Bench

Leading private equity fund, ChrysCapital, has invested in Corona Remedies Private Limited (Corona), one of the country's fastest-growing pharmaceutical companies, by acquiring a 27 per cent stake in it.

The deal creates an exit for private equity firm Creador which has sold its entire stake at a 4X gain on its original investment.

Shardul Amarchand Mangaldas & Co. advised ChrysCapital with a team led by Partners Gunjan Shah and Karun Prakash along with Senior Associate Aayush Sood and Associate Tanay Khanna.

Vertices Partners advised Corona Remedies and its Founders with a team led by Managing Partner Vinayak Burman and Founder Partner Archana Khosla Burman along with Associate Partners Vishal Mehta and Sohini Mandal and Associate Manager Paul Albert.

Cyril Amarchand Mangaldas advised Creador with a team led by Partner Arun Prabhu along with Principal Associate Suvojit Halder.

Clyde & Co’s conduct against partner “verges on bullying”: English court in dispute over bonus

Preferential garbage

Foresight Law Offices is looking to hire a Corporate law Principal Associate in Delhi

Three Months versus Thirty Days: Is Section 34(3) Discriminatory?

Validity of arbitration agreements under the Stamp Act: An overview of the evolving judicial perspective

SCROLL FOR NEXT